Atai Life Sciences N.V. (ATAI)
| Bid | 2.03 |
| Market Cap | 396.72M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -2.56 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.05 |
| Volume | 4,108,239 |
| Avg. Volume (20D) | 2,539,579 |
| Open | 2.15 |
| Previous Close | 2.09 |
| Day's Range | 1.97 - 2.16 |
| 52-Week Range | 1.03 - 2.85 |
| Beta | undefined |
About ATAI
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modul...
Analyst Forecast
According to 4 analyst ratings, the average rating for ATAI stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 389.00% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
15 hours ago · proactiveinvestors.com
atai Life Sciences completes public offering, raising $63.25Matai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter's option to purchase additional shares for gross proceeds of approximately $63.2...
1 week ago · proactiveinvestors.com
atai Life Sciences announces pricing of $55M public offering of sharesatai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwr...
1 week ago · proactiveinvestors.com
atai Life Sciences unveils $55M public offering to advance mental health treatmentsatai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The company may also grant the underwriter a 30-day option to purch...
1 week ago · proactiveinvestors.com
atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial - ICYMIatai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr. Srinivas Rao joined Proactive to discuss promising results from Beckley Psytech's Phase 2a trial for BPL-003 in alcohol use disorder.
2 weeks ago · proactiveinvestors.com
atai Life Sciences-backed psychedelic drug could offer superior value, analysts believeAs psychedelics stocks trade higher following the release of positive data for GH Research's 5-MeO-DMT drug for treatment-resistant depression, analysts at Jefferies believe Beckley Psytech's intranas...
2 weeks ago · proactiveinvestors.com
atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readoutPositive data from Irish biotechnology firm GH Research's Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT), in treatment-resistant depression bodes well for atai ...
3 weeks ago · seekingalpha.com
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another CatalystAtai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results...
3 weeks ago · proactiveinvestors.com
atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analystsatai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for psychedelic drug candidates over the next 12 to 18 months, analysts at Jefferies believe. “See...
3 weeks ago · proactiveinvestors.com
atai Life Sciences unveils positive results from Beckley Psytech's alcohol use disorder trialatai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech's Phase 2a study of BPL-003 (intranasal 5-MeO-DMT benzoate) in alcohol use disorder. The company s...
3 weeks ago · proactiveinvestors.com
Spravato sales surged highlights commercial viability of psychedelics, analysts believeThe latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferie...